ArticleFrontiers in medicine2026
Dynamic changes in serum IL-6, TNF-
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early identification of relapse after first-line chemotherapy remains a major challenge in lymphoma management. Conventional imaging provides limited sensitivity for minimal residual disease and cannot detect early biochemical changes. This prospective cohort study evaluated whether dynamic changes in serum IL-6, TNF- Methods: A total of 260 patients with pathologically confirmed lymphoma who completed standard chemotherapy were enrolled and followed longitudinally. Serum IL-6, TNF- Results: During follow-up, 78 patients (30.0%) experienced relapse. All three biomarkers were significantly elevated in the relapse group at T1, and differences widened at T2 and T3. At T2, IL-6 (adjusted OR = 1.08), β₂-MG (adjusted OR = 1.38), and Ann Arbor stage and IPI score remained independent predictors. β₂-MG exhibited the strongest individual predictive value (AUC = 0.85), while the combined IL-6 + TNF- Conclusion: Longitudinal monitoring of IL-6, TNF-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.